Description

BSE lists 6,44,360 new equity shares of Fredun Pharmaceuticals Limited issued on a preferential basis at Rs. 1250/- per share, effective March 4, 2026, with a lock-in period until September 15, 2026.

Summary

BSE has notified trading members that 6,44,360 new equity shares of Fredun Pharmaceuticals Limited (Scrip Code: 539730, ISIN: INE194R01017) are listed and permitted to trade on the Exchange effective Wednesday, March 4, 2026. These shares were issued on a preferential basis to non-promoters at an issue price of Rs. 1250/- per share (face value Rs. 10/- at a premium of Rs. 1240/-).

Key Points

  • 6,44,360 equity shares of Rs. 10/- each issued at a premium of Rs. 1240/- (issue price Rs. 1250/-)
  • Shares issued to non-promoters on a preferential basis
  • New shares rank pari-passu with existing equity shares of the company
  • Distribution numbers: 4765963 to 5410322
  • Date of allotment: December 29, 2025
  • Trading commences: Wednesday, March 4, 2026
  • Full lock-in applies to all 6,44,360 shares until September 15, 2026

Regulatory Changes

No new regulatory changes introduced. This is a standard listing notice pursuant to SEBI preferential allotment regulations and BSE listing obligations.

Compliance Requirements

  • Trading members must note the new securities and their distribution numbers before permitting trades
  • The lock-in restriction on all 6,44,360 shares (Dist. Nos. 4765963 to 5410322) must be observed until September 15, 2026
  • Trades in these securities should be allowed only from March 4, 2026 onwards

Important Dates

  • Date of Allotment: December 29, 2025
  • Listing / Trading Commencement: March 4, 2026
  • Lock-in Expiry: September 15, 2026

Impact Assessment

The listing adds 6,44,360 shares to the tradeable float of Fredun Pharmaceuticals Limited, though all newly listed shares are subject to lock-in until September 15, 2026, meaning no immediate increase in free-float liquidity. The preferential allotment at Rs. 1250/- signals capital raising activity by the company. Market impact is expected to be minimal given the lock-in period and the relatively small size of the issuance for a listed pharmaceutical scrip.

Impact Justification

Routine listing of preferentially allotted shares for a small-cap pharma company; limited broad market impact, relevant primarily to existing and prospective shareholders of Fredun Pharmaceuticals.